Bharat Immunologicals Gross Profit vs. Net Income

BIBCL -- India Stock  

INR 19.75  1.60  7.49%

The Drivers Module shows relationships between Bharat Immunologicals's most relevant fundamental drivers and provides multiple suggestions of what could possibly affect the performance of Bharat Immunologicals Biologicals Corp Ltd over time as well as its relative position and ranking within its peers. Check also Trending Equities

Bharat Immunologicals Net Income vs. Gross Profit Fundamental Analysis

Bharat Immunologicals Biologicals Corp Ltd is rated below average in gross profit category among related companies. It is rated below average in net income category among related companies making up about  0.06  of Net Income per Gross Profit. The ratio of Gross Profit to Net Income for Bharat Immunologicals Biologicals Corp Ltd is roughly  17.29 
Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Bharat Immunologicals 
Gross Profit 
Cost of Revenue 
48.93 M
Gross Profit varies significantly from one sector to another and tells investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Net income is the profit of a company for the reporting period which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most watched numbers by money managers as well as individual investors.
Bharat Immunologicals 
Net Income 
(Rev + Gain) 
(Exp + Loss) 
2.83 M
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin which measures income as a percentage of sales.

Bharat Immunologicals Net Income Comparison

Bharat Immunologicals is currently under evaluation in net income category among related companies.